⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NBIX News
Neurocrine Biosciences Inc
BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
prnewswire.com
EFX
NBIX
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
prnewswire.com
NBIX
Syndromic Multiplex Panels Market Strategies, Trends and Forecast 2025-2029: Cost Efficiency, Diagnostic Accuracy, Single-Visit Testing, and Pandemic-Driven Uptake Support Growth
globenewswire.com
ABT
BDX
BIIB
CHE
CTAS
CUE
DHR
DIA
EXPE
GEHC
GILD
HOLX
ICUI
ILMN
INCY
ISRG
LH
LULU
MRNA
NBIX
NOC
ORCL
PDD
PFE
QGEN
QDEL
REGN
ROKU
SNPS
TMO
TSLA
VRTX
XRAY
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
prnewswire.com
NBIX
Endometriosis Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
ABBV
NBIX
JNJ
NVS
AMGN
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
prnewswire.com
NBIX
Nona Biosciences Enters into Collaboration Agreement with Link Cell Therapies to Advance CAR-T Cell Therapies
prnewswire.com
NBIX
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
prnewswire.com
NBIX
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
prnewswire.com
NBIX
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
prnewswire.com
NBIX